Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
Latest Information Update: 23 Nov 2025
At a glance
- Drugs SKB-410 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 18 Nov 2025 Status changed from not yet recruiting to recruiting.
- 04 Nov 2025 New trial record